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SHORT COMMUNICATION
Correlation between clinical response to interleukin 2
and HLA phenotypes in patients with metastatic renal
cell carcinoma
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Summary HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32
was associated with a clinical response (PF=0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders
(P=0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some
MHC molecules are more efficient than others for endogenous tumour antigen presentation.
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Recombinant Interleukin 2 (IL-2), alone or in combination with
other agents, has been shown to induce tumour regression in 20 -
30% ofpatients with advanced melanoma or renal cell carcinoma
(RCC) (Rosenberg et al, 1987; Negrier et al, 1989). Because ofthe
severe side-effects observed during systemic administration ofIL-
2, it is important to identify the parameters that would predict clin-
ical response. We have previously demonstrated that patients with
metastatic RCC, for which high pretreatment levels of IL-6 were
detected in the serum, had a very poor prognosis and did not
respond to IL-2 treatment (Blay et al, 1992). The HLA phenotype
represents another candidate for such a correlation. Major histo-
compatibility complex (MHC) products are important factors of
the cellular arm of the immune response. Cytotoxic and helper T
cells recognize processed antigenic peptides presented by MHC
class I or II molecules respectively. The polymorphism of MHC
proteins affects the ability ofdifferent alleles to bind with specific
antigens; it is therefore likely that various HLA haplotypes differ
in their ability to present tumour-specific endogenous antigens.
Lilly et al, (1964) reported an association between histocompati-
bility antigens and susceptibility to virally induced leukaemia in
mice. Further studies demonstrated that a relationship between
susceptibility (Falk et al, 1971; Kantor et al, 1983) or resistance
(Dellon et al, 1975; Oliver et al, 1977) to malignancy and HLA
phenotype could be highlighted in human spontaneous tumours
also, thus supporting the concept ofimmune surveillance in cancer
patients. Further studies were based on these data to evaluate the
association between HLA phenotypes and the likelihood of
response to treatment, particularly in melanoma (Mitchell et al,
1992; Scheibenbogen et al, 1994; Marincola et al, 1995; Rubin
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et al, 1995). In the present study, we report a correlation between
HLA distribution in RCC cancer patients and the predictability of
response to IL-2 based therapy.
PATIENTS AND METHODS
Study population
The present study involved 79 metastatic RCC patients of
European ancestry treated by immunotherapy with IL-2 after
written informed consent. All patients were evaluable for response
to IL-2. Characteristics ofthe patients, therapeutic regimens (West
et al, 1987; Negrier et al, 1989; Atzpodien et al, 1990; Blay et al,
1992; Merrouche et al, 1995) and response to therapy are shown
in Table 1.
HLA phenotyping
HLA phenotyping was performed on peripheral blood mononu-
clear cells using the standard microlymphocytoxicity assay.
Statistical analysis
The frequencies of each single HLA antigen in the 79 patients
were compared with those of a group of 124 normal volunteer
blood donors ofCaucasian origin for HLA class I phenotypes and
a group of 192 donors for HLA class II phenotypes; all were typed
by the same laboratory. The distribution of HLA phenotypes was
then compared between responder and non-responder patients.
Statistical analyses were performed using the Yates corrected chi-
square test and the Fisher's exact test (two-tailed). Each P-value
herein reported should be multiplied by the number of antigens
studied (i.e. 80) to correct for the selection ofan antigen frequency
occuring by chance alone. However, the P-values were reported
uncorrected to facilitate comparison of these values with other
investigations and because such a correction gives too conserva-
tive an estimate (Miller, 1981).
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Table 1 Characteristics of the patients
Characteristics
Sex
Male
Female
Age
Median (year)
Range (year)
WHO performance status
0
1
2
3
No. of metastatic sites
1
>1
Therapeutic regimens
IL-2 (i.v.)
IL-2 (i.v.) + IFNa
IL-2 (s.c.) + INFax
IL-2 (i.v.) + LAK cells
IL-2 (i.v.) + IFNax + LAK cells
IL-2 (i.v.) + TIL
Response to therapy
PR or CR
SD
PD
61
18
55
24-78
41
27
10
1
17
52
(77%)
(23%)
(52%)
(34%)
(13%)
(1%)
(22%)
(78%)
29
17
22
2
8
1
18
24
37
(23%)
(30%)
(47%)
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.
RESULTS
The comparison ofthe distribution ofHLA phenotypes in the RCC
population and in the control population of the same European
Caucasian origin shows a significant difference foronly one single-
locus antigen, B51 (24% vs expected 12%, P=0.027) (Table 2).
The association of HLA phenotypes with clinical response to
IL-2 has been investigated within the RCC population and is
presented in Table 2. No statistical association was noted in this
study between MHC class II phenotype and response.
HLA allele A32 was significantly correlated to response; 5 of
the 18 (28%) responder patients were positive for HLA.A32
compared with 4 of 61 (7%) non-responder patients (P=0.025).
Furthermore, 8 of the 18 (44%) responder patients were positive
for HLA.A3 compared with 14 of the 61 (23%) non-responder
patients, a result which did not reach significance in this series
(P=0.075). A total of 11 of the 18 (61%) responder patients were
A3 and/or A32 compared with 17 of the 61 (28%) non-responder
patients (P=0.008).
When patients were divided into either responders or stable and
progressive-disease patients, an intermediate frequency in the
expression of HLA.A3 and/or A32 was observed in stable-disease
patients compared with responders and progressors (P=0.027)
(Table 3). Finally, the analysis ofthe overall 2-year survival in the
responder and non-responder populations, comparing HLA.A3-
and/or A32-positive vs negative patients, did not show a significant
difference, but the number ofpatients was small (data not shown).
A trend was observed within the responder population with a
2-year survival frequency of 61% for the HLA.A3- and/or A32-
positive responder patients compared with a frequency of28.5% in
the HLA.A3- and/or A32-negative responding population.
Table 2 HLA phenotype frequencies in renal cell cancer patients, responder
patients, non-responder patients and control population
Allele
Al
A2
A3
A9
A10
All
A23
A24
A25
A26
A28
A29
A30
A31
A32
A33
B5
B7
B8
B12
B13
B14
B15
B16
B17
B18
B21
B22
B27
B35
B37
B38
B39
B40
B41
B42
B44
B45
B47
B49
B50
B51
B52
B53
B55
B56
B57
B58
B60
B61
B62
B63
CW2
CW3
CW4
CW5
DR1
DR2
DR3
DR4
DR5
DR6
DR7
DR8
DR9
DR10
DR11
DR12
DR13
DR14
DR15
DR16
DQl
DQ2
DQ3
DQ4
DQ5
DQ6
D07
DQ8
All patients
n (%)
18 22.8
37 46.8
22 27.8
18 22.8
6 7.6
10 12.6
4 5.1
13 16.5
1 1.3
5 6.3
9 11.4
7 8.9
2 2.5
6 7.6
9 11.4
3 3.8
20 25.3
13 16.5
10 12.7
18 22.8
2 2.5
11 13.9
9 11.4
9 11.4
4 5.1
11 13.9
4 5.1
7 8.7
7 8.7
8 10.1
1 1.3
3 3.8
5 6.3
8 10.1
1 1.3
0 0.0
18 22.8
0 0.0
2 2.5
3 3.8
1 1.3
19 24.1a
0 0.0
0 0.0
4 5.1
3 3.8
4 5.1
0 0.0
8 10.1
0 0.0
9 11.4
0 0.0
6 7.6
8 10.1
8 10.1
0 0.0
14 17.7
16 20.6
14 17.7
13 16.5
22 27.8
21 26.6
19 24.1
11 13.9
0 0.0
0 0.0
20 25.3
2 2.5
17 21.5
4 5.1
13 16.5
2 2.5
46 58.2
26 33.0
40 50.1
0 0.0
21 26.6
24 30.4
30 38.0
5 6.3
Control patients
n (%)
33 26.6
54 43.5
31 25.0
30 24.2
12 9.7
13 10.5
4 3.2
26 21.0
4 3.2
8 6.5
11 8.8
16 12.9
7 5.6
13 10.5
12 9.7
4 3.2
19 15.3
14 11.3
19 15.3
38 30.6
3 2.4
8 6.5
16 12.9
11 8.8
10 8.1
14 11.3
12 9.7
5 4.0
10 8.1
20 16.1
6 4.8
6 4.8
5 4.0
18 14.5
4 3.2
1 0.8
34 27.4
4 3.2
3 2.4
9 7.6
3 2.4
15 12.1a
4 3.2
2 1.6
4 3.2
1 0.8
7 5.6
3 2.4
11 8.8
7 5.6
13 10.5
2 1.6
19 15.3
24 19.4
27 21.8
17 13.7
48 25.0
52 27.1
37 19.3
41 21.4
57 29.7
61 31.8
34 17.7
14 7.3
19 1.0
10 0.5
50 26.0
7 3.6
46 24.0
15 7.8
39 20.3
13 6.8
152 79.2
64 33.3
117 60.9
7 3.6
76 39.6
76 39.6
80 41.7
30 15.6
Responders Non-responders
n (%) n (%)
4 22.2 14 23.0
5 27.8 32 52.5
8 44.4 14 23.0
5 27.8 13 21.3
1 5.6 5 8.2
3 16.7 7 11.5
2 11.1 2 3.3
3 16.7 10 16.4
1 5.6 0 0.0
0 0.0 5 8.2
1 5.6 8 13.1
1 5.6 6 9.8
0 0.0 2 3.3
1 5.6 5 8.2
5 27.8b 4 6.6b
0 0.0 3 4.9
4 22.2 16 26.2
4 22.2 9 14.8
4 22.2 6 9.8
3 16.7 15 24.6
1 5.6 1 1.6
3 16.7 8 13.1
3 16.7 6 9.8
0 0.0 9 14.8
0 0.0 4 6.6
4 22.2 7 11.5
1 5.6 3 4.9
2 11.1 5 8.2
1 5.6 6 9.8
1 5.6 7 11.5
0 0.0 1 1.6
0 0.0 3 4.9
0 0.0 5 8.2
2 11.1 6 9.8
1 5.6 0 0.0
0 0.0 0 0.0
3 16.7 15 24.6
0 0.0 0 0.0
0 0.0 2 3.3
1 5.6 2 3.3
0 0.0 1 1.6
4 22.2 15 24.6
0 0.0 0 0.0
0 0.0 0 0.0
0 0.0 4 6.6
2 11.1 1 1.6
0 0.0 4 6.6
0 0.0 0 0.0
2 11.1 6 9.8
0 0.0 0 0.0
3 16.6 6 9.8
0 0.0 0 0.0
1 5.5 5 8.2
1 5.5 7 11.5
2 11.1 6 9.8
0 0.0 0 0.0
5 27.8 9 14.8
5 27.8 11 18.0
2 11.1 12 19.7
2 11.1 11 18.0
7 38.9 15 24.6
4 22.2 17 27.9
3 16.7 16 26.2
3 16.7 8 13.1
0 0.0 0 0.0
0 0.0 0 0.0
6 33.3 14 23.0
1 5.5 1 1.6
3 16.6 14 23.0
1 5.5 3 5.0
4 22.2 9 14.8
0 0.0 2 3.3
12 66.7 34 55.7
5 27.8 21 34.4
10 55.6 30 49.2
0 0.0 0 0.0
7 38.9 14 23.0
4 22.2 20 32.8
10 55.6 20 32.8
0 0.0 5 8.2
ap-0 027. bPF0.025.
British Journal ofCancer(1997) 75(2), 283-286 0 Cancer Research Campaign 1997HLA phenotypes and response to interleukin 2 285
Table 3 Association between clinical response and expression of HLA A3
and/or A32
Number of patients (%)
CR+PR SD PD
A3+ and/or A32+ 11(61%) 8 (33%) 9 (24%)
A3- and A32- 7 (39%) 16 (67%) 28 (76%)
Total 18 24 37
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease. P=0.027 (based on the X2 test).
DISCUSSION
In the present study, the HLA profile of a group of 79 RCC
patients was compared with a control population of Caucasian
origin. Significant variations between the frequencies of HLA
phenotypes in 35 patients with RCC and a control group of normal
volunteer blood donors have already been reported. However, the
elevated frequencies ofHLA.Bw44 and HLA.DR8 observed in the
group of RCC patients were respectively associated with familial
RCC and the German or Scandinavian origin of the patients, a
population group reported to have an elevated risk ofRCC (Kantor
et al, 1983). In contrast, in our series of patients, the higher
frequency of B51 phenotype was not attributable to any peculiar
clinical or ethnical characteristics.
Metastatic RCC, like melanoma, belongs to the small group of
human tumours in which partial (or complete) remission has been
observed in some patients after treatment with various forms of IL-
2-based immunotherapy. In contrast to melanoma, cytotoxic T
lymphocytes (CTL) showing MHC-restricted lysis ofRCC have not
been easily found among tumour-infiltrating lymphocytes (TIL).
Nevertheless, some RCC have been shown to express antigenic
determinants that could be specifically recognized by HLA.A2-
restricted CTL (Schendel et al, 1993; Bernhard et al, 1994).
In this study, HLA.A32 is the only restriction element that
significantly correlates with clinical response to IL-2; however,
differences in the expression of HLA.A3 between responders and
non-responders have also been noted. The association between
some MHC phenotypes and response to therapy strongly suggests
that in vivo, IL-2 may enhance cellular-mediated immunity
directed against a tumour antigen and that some MHC determi-
nants may be more efficient than others for endogenous tumour
antigen presentation.
In this series, although the number of patients is too small to
conclude, the HLA phenotype did not influence the overall
survival of the responding population. Furthermore, when consid-
ering the HLA.A32 determinant individually, among the nine
patients who were A32-positive (11.4%), four did not respond to
IL-2 therapy. For HLA.A3 allele, the proportion ofnon-responding
patients (14/22) is even greater. Thus, this parameter alone is not
sufficient to delineate the subgroup of patients that would benefit
from IL-2 therapy. These data suggest that, in RCC, mechanisms
other than the processing of tumour antigen can lead to immuno-
suppression and tumour progression. Although these mechanisms
have not been completely elucidated, structural and functional
alterations in lymphocytes infiltrating RCC tumours have been
recently described. Other mechanisms, such as the production of
immunosuppressive cytokines (Wang et al, 1995; Menetrier-Caux
et al submitted for publication), alterations in T-cell signal trans-
duction (Finke et al, 1993) or an inefficient co-stimulation by
accessory molecules (Bain et al, 1996), can also be put forward.
Prospective analyses of a larger series of patients are needed in
order to validate these results.
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